Voclosporin Clinical Study Achieves High Complete Remission Rates for Lupus Nephritis
Aurinia Pharmaceuticals has announced top line results from a Phase IIb clinical study of volclosporin for the treatment of lupus nephritis. In this study, nearly half of lupus nephritis patients treated with a low dose of voclosporin, along with standard of care, achieved complete remission after 48 weeks of treatment.
Sandra C. Raymond, president & CEO of the Lupus Foundation of America praised the announcement. “The results of this study are welcome news for patients with lupus. As many as 40 percent of all people with lupus, and as many as two-thirds of all children with the lupus, will go on to develop lupus-related kidney disease. Having an effective treatment with fewer side effects and long-terms health risks will be a great advance to improving the quality of life for people with lupus.”
Read the complete company press release on their website. A phase III trial of voclosporin is expected to begin during the second quarter of 2017.